Business
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also current
About this update from Xilio Therapeutics, Inc.
[{"type":"image","alt":"Catalyst Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Catalyst Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":291,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/acd4b49518224322238ae470f071342d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D7rqLycsFEMrXMBp0B5H3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/acd4b49518224322238ae470f071342d","width":291,"height":95}},"lazy":false},{"type":"text","content":"CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors.","length":226,"tagName":"p"},{"type":"text","content":"Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases.","length":486,"tagName":"p"},{"type":"text","content":""Dan brings an exceptional combination of strategic insight, rare disease expertise, and business development acumen, making him an outstanding addition to our Board," said Patrick J. McEnany, Chairman of the Board of Catalyst. "His leadership in advancing transformative therapies, paired with a proven history of delivering results across the full development continuum, will be instrumental as Catalyst continues to execute its disciplined growth strategy, which includes maximizing our current rare disease portfolio and acquiring strategically aligned assets."","length":585,"tagName":"p"},{"type":"text","content":"From 2008 to 2023, Dr. Curran held roles of increasing responsibility at Takeda Pharmaceutical Company, serving as Senior Vice President and Head of the Rare Genetics and Hematology Therapeutic Area Unit from January 2019 through December 2023.","length":244,"tagName":"p"},{"type":"text","content":""I'm honored to join the Board of Catalyst and...